Journal of Blood Disorders and Transfusion最新文献

{"title":"The outcome of preoperative transfusion guideline on sickle cell disease patients at King Fahd Hospital, Jeddah, KSA","authors":"S. Felemban, R. Bajoria, Amani Alsawaf, R. Chatterjee, Abdulelah Qadi","doi":"10.4172/2155-9864.1000381","DOIUrl":"https://doi.org/10.4172/2155-9864.1000381","url":null,"abstract":"Background: We developed a local hospital preoperative transfusion guideline for sickle cell disease (SCD) patients to reduce the perioperative and the postoperative complications. This study was conducted to evaluate the outcome of clinical practice on SCD patients undergoing surgeries in our institution. \u0000Methods: A retrospective review of 75 SCD patients undergoing surgery at King Fahd Hospital, Jeddah, Saudi Arabia was conducted between April 2005 and May 2010. The medical records were reviewed to define the perioperative risks and the postoperative complications in relation to the type of transfusion modality selected. \u0000Results: The medical records of 75 SCD patients who underwent surgeries were reviewed to define the perioperative risks and the postoperative complications in relation to the type of transfusion modality selected. Preoperatively, 25.3% had complete exchange transfusion (CETX), 17.3% had partial exchange transfusion (PETX), 26.7% had simple top up transfusion (STX) and 30.7% did not require transfusion (NTX). The postoperative complications included vasoocclusive crises (VOC) in 20%, acute chest syndrome (ACS) in 2.7%, and fever in 16% cases. 33.3% patients required the prolonged period of the hospital stay. In the patients of our study, postoperative fever, VOC, ACS, and the length of hospital stay did not show any difference regardless of types of transfusion modalities. However, the correlation was highly significant between the pre-operative haemoglobin (Hb) level and postoperative fever (P<0.01) and VOC (P<0.01). \u0000Interestingly, SCD patients who received hydroxyurea had less postoperative complications such as fever (P<0.05) and vaso-occlusive crises (P<0.05), while those who received prophylactic heparin in the postoperative period had a reduced length of hospital stay (P<0.01) and vaso-occlusive crises (P<0.01). \u0000Conclusion: The guidelines for preoperative transfusion in SCD patients were effective in reducing the postoperative morbidity and mortality. Moreover, this guideline emphasises the operative situations where preoperative transfusion is needed and optimum regimen is required for different surgical operations sub-types.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121875451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Risk for Social/Emotional Difficulty in Adolescents with Sickle Cell Disease Using the Pediatric-Symptom-Checklists","authors":"S. Inoue, D. CrystalCedernaMekoPsy, Tammy Scherrer Rn, Jenny LaChance Ms","doi":"10.4172/2155-9864.1000377","DOIUrl":"https://doi.org/10.4172/2155-9864.1000377","url":null,"abstract":"The Pediatric Symptom Checklist (PSC) is used to screen for social/emotional difficulty in youth. It is completed by either a parent (PSC) or patient (Y-PSC). The Achenbach Child Behavior Checklist (CBCL) and Youth Self-Report (YSR) are parent- and self-completed social/emotional assessment tools that are well validated, but the less validated PSC and Y-PSC’s availability, convenience, and cost are advantageous for busy clinics. Objective: We examined the appropriateness of using the PSC and Y-PSC to screen adolescents with sickle cell disease for social/ emotional difficulty. Method: Patients with sickle cell disease (n=14; 7 female; mean age ± SD= 4.1 ± 1.8) completed the Y-PSC and YSR, while their parents completed the PSC and CBCL. Rates of risk for social/emotional difficulty were compared between parent-completed forms (PSC versus CBCL), and between patient-completed forms (YPSC and YSR). Agreement in the presence or absence of risk was explored as well. Results: Six youth had total scores exceed cutoffs for a positive screen. Parent-completed questionnaires each identified 4 youth; the YSR and Y-PSC identified 4 and 2 respectively. However, no 2 tools identified the exact same combination of youth and no single informant or tool captured all youth with risk for social/emotional difficulty. Conclusion: Our results, though preliminary, indicate that no single informant or screening tool sufficiently captures risk for social/emotional difficulty in the adolescent sickle cell population. Instead, a multi-informant, multi-method approach to screening for social/ emotional difficulty in adolescents with sickle cell disease is encouraged until additional research can illuminate an alternative.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127166497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy","authors":"F. Aung, C. Dinardo, Fern, O. Martínez, S. Pierce, N. Daver, T. Kadia, E. Jabbour, H. Kantarjian, B. Lichtiger, E. Freireich","doi":"10.4172/2155-9864.1000376","DOIUrl":"https://doi.org/10.4172/2155-9864.1000376","url":null,"abstract":"Background: Patients with Acute Myeloid Leukemia (AML) experience profound neutropenia; infections remain the leading cause of morbidity and mortality. Transfusion of functional non-irradiated allogeneic granulocytes may treat or prevent infections in AML patients, and may also have anti-leukemic benefits. \u0000Study Design: Patients free of infection, with a diagnosis of AML or high-risk myelodysplastic syndrome undergoing induction or first-salvage therapy were eligible. Allogeneic Granulocyte Transfusions (GTs) were administered to neutropenic (<0.5 × 109/L) patients every 3-4 days until sustained ANC recovery, initiation of new therapy, or completion of 6 weeks on study. \u0000Results: 45 patients enrolled with a median age of 67 years (range 23-83); 27 (60%) were male. Five patients (11%) never received a GT, due to donor screening failure and/or donor unavailability. 119 donors donated 156 granulocyte concentrates to the remaining 40 patients. The median number of GTs transfused per patient was 3 (range 1-9). All patients experienced >1 neutropenic fever, with an average of one infectious episode per patient. Other adverse reactions were urticaria/pruritis (n=1), rash (n=1), and hypotension (n=1). Response to leukemiadirected therapy included complete remission in 50%, overall response rate of 70%, and 8-week mortality of 8%. Median overall survival was 15 months, with 51% 1-year survival. \u0000Conclusion: Administration of non-irradiated functional allogeneic GTs to neutropenic MDS/AML patients is safe and feasible. No transfusion-associated graft-versus-host-disease (TA-GVHD) was reported and no increased toxicity was described, including among the 10% receiving subsequent allogeneic stem cell transplant. The favorable patient outcomes within this diverse group of primarily elderly AML are notable.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123498579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Cobalamin Therapy for the Patient with Biermer’s Disease","authors":"E. Andrès","doi":"10.4172/2155-9864.1000E117","DOIUrl":"https://doi.org/10.4172/2155-9864.1000E117","url":null,"abstract":"Biermer’s disease also called: Addison’s anemia or in old textbooks, pernicious anemia, is an autoimmune disease, caused by impaired absorption of cobalamin (vitamin B12) owing to the neutralization of intrinsic factor action in the setting of immune atrophic gastritis [1]. In adults and elderly patients, this form of megaloblastic anemia is one of the leading causes of cobalamin deficiency, with the recent described and recognized disorder called food-cobalamin malabsorption. Biermer’s disease, as several autoimmune disorders, has a genetic component.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"87 11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126297445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactate Dehydrogenase (LDH) as Prognostic Marker in Acute Leukemia Quantitative Method","authors":"W. Elbossaty","doi":"10.4172/2155-9864.1000375","DOIUrl":"https://doi.org/10.4172/2155-9864.1000375","url":null,"abstract":"Lactate dehydrogenase enzyme was found in animal and human and play important role in gluconeogenesis process. It distributed in all organs, but the mainly distributed in liver. To evaluated the level of lactate dehydrogenase (LDH) in acute leukemia and investigated its clinical significance with other hematological and clinical parameters. Serum lactate dehydrogenase (LDH) level was investigated in 50 patients with acute leukemia, 17 patients with acute lymphoblastic leukemia and 33 patients with acute myeloid leukemia, in addition to 20 healthy control cases. The relationship between lactate dehydrogenase level and blood cells were analyzed. LDH level was significant elevated in acute leukemia cases as compared to control group, also LDH level was statistically significant increase in acute lymphoblastic leukemia than in acute myeloid leukemia (p<0.001). There were positively correlation between LDH and white blood cells, bone marrow blasts and uric acid; on the other hand, there were negatively correlation between LDH and red blood cells, and platelets. Lactate dehydrogenases represented as supplementary enzymatic tool can be used as differentiation marker between the different types of leukemia not only but also, follow up the patients during treatment period.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122633083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Crystalloid vs. Crystalloid plus Colloid Infusion on the Coagulation System in Patients Undergoing Cancer Breast Surgery","authors":"E. Nasreldin, N. Gamal, A. Darwish","doi":"10.4172/2155-9864.1000374","DOIUrl":"https://doi.org/10.4172/2155-9864.1000374","url":null,"abstract":"Background: To explore whether administration of routinely used intravenous solutions differently affects the coagulation system in breast cancer patients undergoing surgery receiving crystalloid alone or plus colloid fluid regimen. \u0000Patients and Methods: The study included 60 female cancer breast patients scheduled for surgery; patients were randomized to undergo acute normovolemic hemodilution with either crystalloid or crystalloid plus colloid. Six samples were collected from each patient at different period of the study. \u0000Results: IV administration of crystalloid plus colloid as well as crystalloid fluid cause significant effect in coagulation factors variables which is more obvious in administration of both crystalloid and colloid fluid together; where most investigated coagulation variables were significantly increased or decreased. This recorded variation reverts to normal value after 24 hour of infusion samples \u0000Conclusion: Generally the least effect was observed in the group receiving crystalloid; special consideration should be given to the use of colloid rather than crystalloid solutions for rapid fluid loading.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130816043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoral Swelling in a Neonate: Airway Management a Challenge","authors":"V. Asthana, S. Singh, Abhishek Deshwal, T. Singh","doi":"10.4172/2155-9864.1000283","DOIUrl":"https://doi.org/10.4172/2155-9864.1000283","url":null,"abstract":"Foregut duplications occurring in tongue have very few reports in literature. These oral and esophageal lesions may cause feeding and respiratory difficulties. For surgical excision securing airway in these babies is very challenging, as visualization of glottis is hampered, because of lack of space in the mouth. We report a case of twelve hours old neonate referred to our institute for the excision of intraoral swelling under general anaesthesia which was revealed as gastric duplication cyst histopathologically.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130128527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Study on Blood and Blood Components Transfusion, Adverse Reaction at a Tertiary Care Teaching Hospital, Bangalore","authors":"M. Vidyashree, T. Vithya, S. Prasad, Shobha Rani Rh","doi":"10.4172/2155-9864.1000372","DOIUrl":"https://doi.org/10.4172/2155-9864.1000372","url":null,"abstract":"Background: Blood transfusion is the transfer of whole blood or blood components (red blood cells only or blood plasma only) into the bloodstream directly or into the bone marrow. Blood transfusion is carried out between two identical blood groups only, which otherwise (incompatible blood transfusion) results in agglutination or clumping of the blood leading to haemolysis of RBC and releasing the haemoglobin to the blood plasma. \u0000Blood and blood components: Blood is a liquid connective tissue that consists of blood plasma (liquid) and formed elements (red blood cells, white blood cells and platelets). Blood components are various parts of blood like Red Blood Cells, Granulocytes and plasma separated from one another by conventional blood bank method by centrifugation because of their different specific gravities. \u0000The different cellular components are Red Blood cell (RBC) or Packed Red cells (PCV), Leucocyte depleted Red cells, Platelet concentrate, Platelet Apheresis and Leucocyte depleted Platelet concentrate. The different plasma components are Fresh Frozen Plasma, Cryoprecipitate and Cryo-poor Plasma. \u0000Indications for blood and blood component transfusion: Some of the conditions that demand the transfusion of blood and blood components are red cell replacement in anemia, acute or chronic restoration of oxygen carrying capacity, IgA deficiency, Thrombocytopenia, loss of blood during surgery and delivery and clotting factor deficiency. \u0000Common problems during blood transfusion: Blood transfusions are associated with adverse reactions during or after the transfusion. \u0000The blood transfusion reactions are classified based on the onset of the reaction, acute– immediate and delayed–days to weeks to months. The reactions are as follows: \u0000Acute transfusion reaction: Mild (Category 1) – urticarial reaction. \u0000Moderate (Category 2) – Severe hypersensitivity reaction, Febrile non-hemolytic reactions, Bacterial contamination, Pyrogens. \u0000Severe (Category 3) – Acute intravascular haemolysis, Septic shock, Fluid Overload, Anaphylactic shock, TRAIL (transfusion-associated acute lung injury). \u0000Delayed transfusion reaction: Transfusion Transmissible infections – HIV 1 and 2, Viral Hepatitis B and C, Syphilis, Malaria, HTL V 1and 2, Cytomegalovirus, Chagas Disease. Others - Delayed Haemolytical, Post Transfusion Purpura, GvHD, Iron overload. Thus, the blood transfusions are needed to be monitored carefully. The monitoring has to be done pre-transfusion, during transfusion and post-transfusion for the safety and benefits of the patient.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126260606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Importance of PRAME Gene Expression in Acute Myeloid Leukemia","authors":"A. Baraka, M. Hashem, S. Elshorbagy, Mona Hassanein, Salah F. Elsayed","doi":"10.4172/2155-9864.1000373","DOIUrl":"https://doi.org/10.4172/2155-9864.1000373","url":null,"abstract":"Background: The PRAME (preferentially expressed antigen of melanoma) gene is frequently over expressed in a wide variety of malignant diseases, including acute myeloid leukemia (AML). \u0000Objective: To investigate the expression of PRAME gene in AML and its importance in the prognosis. Patients and methodsThe transcript level of PRAME gene was detected in peripheral blood specimens from 72 de novo AML patients and 40 control subjects by using real-time quantitative PCR and the prognostic value of PRAME was determined through treatment outcome and survival analysis. \u0000Results: PRAME gene was highly expressed in 74% of de novo AML cases while low expression was detected among healthy controls, the mean value of PRAME gene expression was highest among M3 AML subtype and lowest among M5b AML subtype. No significant correlation could be observed between PRAME gene expression and different CBC parameters, age, gender or cytogenetics, but there was a significance positive correlation between PRAME gene expression with treatment outcome, disease free survival (DFS) and overall survival. \u0000Conclusion: PRAME gene over expression might be a good prognostic factor of AML and could be a useful target for immunotherapy.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124430992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mandatory Blood Donor Screening for Human T-Cell Lymphotropic Virus Type I and Type II in Saudi Arabia: Need for Review","authors":"Hanat S. Mohamud, E. Alghamdi, A. Alhetheel, F. Almajid, A. Ahmed, A. Somily, D. Mohamed","doi":"10.4172/2155-9864.1000371","DOIUrl":"https://doi.org/10.4172/2155-9864.1000371","url":null,"abstract":"Background: HTLV blood donor screening is recommended practice in high prevalence countries. However, although studies of HTLV seroprevalence in Saudi Arabia agree these viruses present limited threat in the country, serological screening of HTLV-I/-II in all prospective blood donor candidates is mandatory practice. Since the last publication of HTLV seroprevalence in Saudi Arabia 10 years ago, we review 2014-2015 data of 23,668 blood donors attending King Khalid University Hospital (KKUH) Riyadh, to determine whether this mandatory practice needs review. Materials and methods:Serology screening was performed on the Abbott Architect system running the rHTLV assay. Repeat reactive results were confirmed by Western Blot analysis. Results: This study revealed zero HTLV-I/-II seroprevalence amongst 23,668 donors over the study period. Discussion: We further support Saudi Arabia as a HTLV non-endemic region, and review more cost-effective strategies to minimize HTLV risks as an alternative to mandatory blood donor screening.","PeriodicalId":182392,"journal":{"name":"Journal of Blood Disorders and Transfusion","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130164907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}